Journals / Acta Medica Alanya / 2021 / Cilt: 5 - Sayı: 2

The relationship between the changes in inflammatory parameters and response to treatment in major depression patients starting antidepressant treatment

Antidepresan tedavi başlanan major depresyon hastalarında inflamatuar parametrelerdeki değişikliklerin tedavi yanıtı ile ilişkisi

Pages
118–125
Publication Date
2022-09-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Considering that the pathophysiology ofdepression is quite complex, it could be argued that a single group of blood testsmay not be sufficient to explain the link between inflammation and depression.Considering all the limitations of the study, a future a prospective study to prove theinflammatory hypothesis in MDD, including the detailed blood, BOS tests, along withmore comprehensive neuroimaging parameters on the brain pathways, might providemore effective results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Changes in inflammatory parameters such as cytokines, stress hormonesand C reactive protein that occur in depression, are important in understanding thepathophysiology of depression and developing new treatment approaches.
📊
Key Findings & Data:According to theretrospective records of the last five years in the psychiatry outpatient clinic ofAlanya Alaaddin Keykubat University Training and Research Hospital, the patientsdiagnosed with Major Depressive Disorder (MDD), started on single antidepressanttreatment for the first time and who used antidepressant treatment for at least 6-8weeks, were included in the study.
💡
Conclusion & Impact:Considering that the pathophysiology ofdepression is quite complex, it could be argued that a single group of blood testsmay not be sufficient to explain the link between inflammation and depression.Considering all the limitations of the study, a future a prospective study to prove theinflammatory hypothesis in MDD, including the detailed blood, BOS tests, along withmore comprehensive neuroimaging parameters on the brain pathways, might providemore effective results.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Changes in inflammatory parameters such as cytokines, stress hormonesand C reactive protein that occur in depression, are important in understanding thepathophysiology of depression and developing new treatment approaches. The mainpurpose of this study was to determine the changes in inflammatory markers inpatients with major depression, before and after antidepressant treatment, as well asto determine the effect of antidepressant treatment types on these changes.Methods: This study was a single center, retrospective study. According to theretrospective records of the last five years in the psychiatry outpatient clinic ofAlanya Alaaddin Keykubat University Training and Research Hospital, the patientsdiagnosed with Major Depressive Disorder (MDD), started on single antidepressanttreatment for the first time and who used antidepressant treatment for at least 6-8weeks, were included in the study. Patients whose Hamilton Depression Rating Scale(HDRS), complete blood count, C reactive protein and cortisol values were reachedfrom the system during MDD treatment, constituted the sample of the study.Results: In the present study, after the antidepressant treatment, while HDRSscores decreased significantly in patients with Major Depression compared to beforetreatment (p 0,05). This conditionwas independent of the type of antidepressant used in the treatment (p>0,05 inthe SSRI treatment group, p>0,05 in the SNRI treatment group). In addition, it wasobserved that the decrease in depression scores was not associated with the typeof antidepressant (p=0,001, in the SSRI treatment group, p=0,005, in the SNRItreatment group).Conclusion: Results to support the inflammatory hypothesis in Major DepressiveDisorder were not conclusive in this study. Considering that the pathophysiology ofdepression is quite complex, it could be argued that a single group of blood testsmay not be sufficient to explain the link between inflammation and depression.Considering all the limitations of the study, a future a prospective study to prove theinflammatory hypothesis in MDD, including the detailed blood, BOS tests, along withmore comprehensive neuroimaging parameters on the brain pathways, might providemore effective results.

Özet

Amaç: Depresyonda meydana gelen sitokinler, stres hormonları ve C reaktif protein gibi inflamatuvar parametrelerin değişimi, depresyonun patofizyolojisinin anlaşılması ve yeni tedavi yaklaşımlarının geliştirilmesi açısından önem taşımaktadır. Bu çalışmanın temel amacı, major depresyon hastalarında antidepresan tedavi öncesi ve sonrasında inflamatuvar belirteçlerde nasıl bir değişiklik olduğunu tespit etmek ve antidepresan tedavi türünün bu değişiklikler üzerindeki etkisini belirlemektir. Yöntem: Tek merkezli, retrospektif olarak gerçekleştirilen çalışmada, Alanya Alaaddin Keykubat Üniversitesi Eğitim ve Araştırma Hastanesi psikiyatri polikliniğinde son beş yıla ait geriye dönük incelenen kayıtlara göre, Majör Depresif Bozukluk (MDB) tanısı konulup, ilk kez tekli antidepresan tedavisine başlanan ve en az 6-8 hafta antidepresan tedavi kullanmış, tedavi öncesi ve sonrası Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ), tam kan sayımı, C reaktif protein, kortizol değerlerine ulaşılabilen hastalar çalışmanın örneklemini oluşturmuştur. Bulgular: Çalışmamızda, antidepresan tedavi sonrası, HDDÖ puanları Majör Depresyonlu hastalarda tedavi öncesine göre anlamlı olarak azalırken (p 0,05). Bu durum, tedavide kullanılan antidepresan ilaç türünden bağımsızdır (SSRI tedavi grubunda p>0,05, SNRI tedavi grubunda p>0,05). Ayrıca depresyon puanlarındaki azalmanın da, antidepresan ilaç türü (SSRI-SNRI) ile ilişkili olmadığı belirlenmiştir (SSRI tedavi grubunda, p=0,001, SNRI tedavi grubunda, p=0,005). Sonuç: Çalışmamızda, MDB’de inflamatuar hipotezi destekleyecek sonuçlar belirlenmemiştir. Depresyonun patofizyolojisinin oldukça karmaşık olduğu düşünüldüğünde, inflamasyon ve depresyon arasındaki bağlantıyı açıklamak için yalnızca bir grup kan testinin yeterli olmayabileceği düşünülebilir. Çalışmamızdaki tüm sınırlılıklar göz önünde bulundurulduğunda, gelecekte daha kapsamlı kan, BOS testleri ile beraber beyin yolaklarına ilişkin nörogörüntüleme parametrelerini de içeren prospektif çalışmalar, MDB’de inflamatuar hipotezi kanıtlamak için daha etkili sonuçlar sağlayabilir.

🔖

Cite This Article

ÇANKAYA, Ş., UYGUR, A. B. (2022). The relationship between the changes in inflammatory parameters and response to treatment in major depression patients starting antidepressant treatment. Acta Medica Alanya, Cilt: 5 - Sayı: 2, 118–125. https://ajindex.com/articles/425772

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Guilbert J. The world health report 2002–reducing risks, promoting healthy life. Educ Health. 2003;16:230. PMID: 14741909
  2. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA. 2003;100:1920-5. PMID: 12578963
  3. Aschbacher K, Epel E, Wolkowitz O, Prather A, Puterman E, Dhabhar F. Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. Brain Behav Immun. 2012;26:346-52. PMID: 22119400
  4. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008; 455:894-902. PMID: 18923511
  5. Woelfer M, Kasties V, Kahlfuss S, Walter M. The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder. Neuroscience. 2019;403:93-110. PMID: 29604382
  6. Carvalho L, Torre J, Papadopoulos A, Poon L, Juruena M, Markopoulou K, et al. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disorder. 2013;148:136-40. PMID: 23200297
  7. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-41. PMID: 19150053
  8. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31. PMID: 16316783
  9. Yulug B. Neuroprotective treatment strategies for poststroke mood disorders: A minireview on atypical neuroleptic drugs and selective serotonin re-uptake inhibitors. Brain Res Bull. 2009;80:95-9. PMID: 19576272
  10. Yuluğ B, Ozan E, Kilic E. Brain-derived neurotrophic factor polymorphism as a genetic risk for depression? A short review of the literature. J Neuropsychiatry Clin Neurosci. 2010;22:123. E5-6. PMID: 20160224
  11. Lapchak PA, Zhang JH. Neuroprotective therapy for stroke and ischemic disease. Switzerland: Springer International Publishing, 2017. p. 607-20. doi:10.1007/978-3-319-45345-3
  12. Cai L, Xu L, Wei L, Chen W. Relationship of mean platelet volume to MDD: a retrospective study. Shanghai Arch Psychiatry. 2017;29:21-9. PMID: 28769542
  13. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, Kunkel SL. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:273-9. PMID: 16101533
  14. Amodeo G, Trusso MA, Fagiolini A. Depr